[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rhinitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rhinitis":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,88,111,137,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100622428","rhinavevaluation-of-treatments-for-acute-viral-rhinitis-rhinosinusitis-and-rhinopharyngitis-100622428",false,"NCT07383493","RhinAV_Evaluation of Treatments for Acute Viral Rhinitis, Rhinosinusitis, and Rhinopharyngitis","Evaluation of Treatments for Acute Viral Rhinitis, Rhinosinusitis, and Rhinopharyngitis","RhinAV","Inclusion Criteria:\n\n* Acute viral rhinitis or acute rhinosinusitis or viral rhinopharyngitis (sneezing, rhinorrhea, nasal obstruction, cough secondary to posterior rhinorrhea, sore throat) that began less than 72 hours prior to the inclusion visit, in the investigator's judgment,\n* Effective contraception for female patients of childbearing age.\n* Cooperation and sufficient understanding to comply with the requirements of the trial.\n* Acceptance of registration in the SI-RIPH VRB file.\n* Having received informed information and agreeing to give written consent.\n* Affiliated with the French Social Security system.\n\nExclusion Criteria:\n\n* Hypersensitivity\u002Fhistory of allergy to any of the product's components,\n* Complicated rhinitis, rhinosinusitis, or rhinopharyngitis (acute bacterial sinusitis, acute otitis media, acute bronchitis, or pneumonia) or severe cough that is poorly tolerated,\n* Chronic rhinosinusitis,\n* Allergic rhinosinusitis,\n* Other ongoing treatments for acute rhinitis (local treatment, antitussives, antibiotics, antiretrovirals, corticosteroids, etc.),\n* Positive antigen test for influenza A\u002FB or COVID-19 and infection requiring etiological treatment according to the recommendations,\n* Bacterial rhinopharyngitis with positive TROD test\n* Comorbidities or health conditions deemed incompatible with the trial by the investigator,\n* Recent ENT surgery (\\\u003C6 months),\n* ENT pathology such as nasal septum deviation or other causes of nasal obstruction,\n* Pulmonary pathology (COPD, asthma, etc.),\n* Immunosuppression (as reported by the patient),\n* Pregnant or breastfeeding women,\n* Currently participating in another clinical trial, or in the exclusion period, or having received total compensation of more than €6,000 in the 12 months prior to the start of the trial,\n* Benefiting from legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial protection).","ALL","18 Years","70 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this study is to conduct post-marketing clinical follow-up of four products: NS, NHE, NHG, and PIR. This follow-up will consist of collecting clinical data in real-life conditions to confirm the tolerance, safety, and efficacy of medical devices used in the treatment of acute viral rhinitis, rhinosinusitis, and rhinopharyngitis, while also assessing the benefit\u002Frisk ratio of the products.",[28,29,30,31,32,33],"Rhinitis Acute","Rhinitis Viral","Rhinosinusitis Acute","Rhinopharyngitis","Rhinitis","Rhinosinusitis","RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-15","ACTUAL",{"date":40,"type":38},"2026-02-25",{"date":42,"type":22},"2027-03",{"name":44,"class":45},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100619721","phase-3-efficacy-and-safety-of-slit-in-patients-with-rhinitisrc-withwithout-mild-moderate-asthma-due-to-dpt-andor-df-100619721","NCT07348302","Efficacy and Safety of SLIT in Patients With Rhinitis\u002FRC With\u002FWithout Mild-moderate Asthma, Due to Dpt and\u002For Df","Prospective, Randomised, DBPC, Multicenter Clinical Trial to Evaluate Efficacy and Safety of Sublingual Immunotherapy in Patients With Rhinitis\u002FRhinoconjunctivitis With or Without Mild to Moderate Asthma, Allergic to Dpt and\u002For Df","Oraltek-58","Inclusion Criteria:\n\n1. Participants who have signed and dated Informed Consent Form (ICF).\n2. Female or male aged 12 to 65 years, both included, at the time of signature of ICF.\n3. Participants with confirmed clinical history of inhalation allergy with intermittent or persistent moderate-severe rhinitis\u002F rhinoconjunctivitis according to the ARIA classification(1) of at least 1 year of duration (treated with anti-allergic medication) with or without mild-moderate controlled intermittent or persistent asthma according to the definition of GINA 2022(2) caused by Dermatophagoides pteronyssinus and\u002For Dermatophagoides farinae.\n4. Participants with positive skin prick test and a wheal major diameter ≥ 5 mm to a standardized allergen extract of Dermatophagoides pteronyssinus and\u002For Dermatophagoides farinae.\n5. Women of childbearing age (i.e., following menarche and until postmenopause, defined as no menses for 12 months without an alternative medical cause, or non-subject to permanent sterilisation methods, such as hysterectomy, bilateral salpingectomy and bilateral oophorectomy) must have a serum pregnancy test negative result, and a confirmed menstrual period before enrolling the study.\n6. Women of childbearing age must commit to using a highly effective contraception method during the trial and up to 1 month after the end of treatment with the investigational medicinal product (IMP). Such methods include: combined (estrogen and progestogen containing) hormonal, contraception. associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, male condom, diaphragm used with spermicide, bilateral tubal occlusion, vasectomized partner or sexual abstinence.\n7. Participants capable of complying with dosage regimen.\n8. Participants owning a smartphone to register symptoms and medication consumption.\n9. Participants not sensitized to any other clinically relevant allergen or sensitized with the following characteristics (sensitization to other allergens will be assessed through skin prick test in Europe and LATAM and through IgE levels in China):\n\n   1. Participants sensitized to dander (with a positive skin prick test for dander or IgE ≥ 0.35 kU\u002FL), provided that they have occasional exposure and symptoms.\n   2. Participants sensitized to endemic pollen (with a positive skin prick test or IgE ≥0.35 kU\u002FL) will be scheduled to be included so that the pollen season does not coincide with the Baseline Evaluation Period nor with one month before and after the Main Evaluation Period. In LATAM, grass sensitized participants will not be included.\n10. Participants not sensitized to moulds, cockroach, Blomia tropicalis or other geographically relevant mites (negative skin prick test or IgE \\\u003C 0.7 kU\u002FL).\n11. Participants with a RCSMS ≥ 3 out of 6 recorded for at least 10 days during the baseline evaluation period, corresponding to moderate-to-severe allergic rhinitis\u002Frhinoconjunctivitis.\n12. Participants with specific IgE against a complete extract of D. pteronyssinus and \u002F or D. farinae or any of the molecular components of allergenic sources with a value ≥ 3.5kU\u002FL.\n\nExclusion Criteria:\n\n1. Participants who have received previous immunotherapy to any of the tested allergen during the last 5 years or any desensitization process in the last 2 years (e.g., oral immunotherapy \\[OIT\\], milk, or egg) before the second screening visit (S2), or currently receiving immunotherapy with any other allergen.\n2. Those cases in which allergen-specific immunotherapy (AIT) would be a contraindication according to the criteria of European Allergy and Clinical Immunology Immunotherapy Subcommittee.(3)\n3. Asthmatic participants with forced expiratory volume in the first second (FEV1) \\\u003C80% (following at least a 6-hour washout of short-acting beta2 agonists \\[SABA\\] and 12-hour washout of long-acting beta2 agonists \\[LABA\\]) despite pharmacological treatment by the time of enrolment.\n4. Participants with uncontrolled asthma, according to GINA 2022,(2) asthma with poor symptom control (frequent symptoms or reliever use, activity limited by asthma, night waking due to asthma) and\u002For frequent exacerbations (≥2\u002Fyear) requiring oral corticosteroids (OCS), or serious exacerbations (≥1\u002Fyear) requiring hospitalization.\n5. Participants with severe asthma, according to GINA 2022,(2) on Step 4 or 5 treatment, who had poor symptom control and had good adherence and inhaler technique.\n6. Participants on treatment with β-blockers or angiotensin-converting enzyme (ACE) inhibitor.\n7. Participants on treatment with immunosuppressive or biological drugs.\n8. Participants who had not had a long enough washout\u002Fwithdrawal period at the first screening visit (S1) according to criteria in the study protocol (See Table 6 in section 9.5.3) before undergoing allergen diagnostic tests (skin prick test or IgE analysis).\n9. Unstable participants who have suffered a respiratory tract infection and\u002For asthma exacerbation within 4 weeks prior to first screening visit (S1).\n10. Participants who have suffered chronic urticaria, severe anaphylaxis, or with hereditary angioedema history within 2 years prior to the first screening visit (S1).\n11. Participants having any contraindication for the use of adrenaline (e.g., hyperthyroidism, heart disease, or hypertension) according to the investigator's criteria.\n12. Participants with other severe diseases not related to allergic rhinitis or asthma that could interfere with the study treatment or the follow-up.\n13. Participants with severe and unresponsive to treatment autoimmune diseases (e.g., thyroiditis or lupus), tumoral diseases or immunodeficiencies.\n14. Participants that could not comply with the study protocol, according to the investigator's criteria, or have a serious mental illness.\n15. Participants with known allergy to any of the components of the study treatment other than study allergens.\n16. Participants who had a complication(s) of any nasal disease (including nasal polyp, nasal septal deviation, and hypertrophic rhinitis, drug-induced rhinitis and\u002For non-allergic rhinitis) affecting an appropriate evaluation of the efficacy and\u002For safety, according to investigator's criteria.\n17. Participants who had a nasal surgery within 6 months prior to the first screening visit (S1) or have programmed or anticipated nasal surgery during the trial period.\n18. Participants with a lesion in the oral cavity that could confound the safety profile of the study treatment, according to the investigator's criteria.\n19. Participants who required treatment with antihistamines and\u002For corticosteroids for other purposes than alleviating symptoms of allergic rhinitis (except temporal use for diseases such as common colds).\n20. Participants with lower respiratory tract diseases different from asthma as emphysema, bronchiectasis, or chronic obstructive pulmonary disease.\n21. Breastfeeding or pregnant women.\n22. Participants who are immediate family members of the investigator.\n23. Concurrent participation in other clinical trials or previous participation within 30 days prior to the first screening visit (S1).\n24. Participants with history of serious systemic reactions, including food, Hymenoptera venom, medications, etc.\n25. Participants expected to have marked changes (e.g., moving) in the circumstances of life during the study.\n26. Participants who plan to start using anti-mite bedding or similar equipment during the study.\n27. Participants who are considered inappropriate for the study, according to the investigator criteria.","12 Years","65 Years",{"count":58,"type":22},736,[60],"PHASE3","The goal of this clinical trial is to learn if MM09 works to treat patients allergic to house mites, displaying rhinitis\u002Frhinoconjunctivitis with or without mild to moderate asthma. It will also learn about the safety of MM09. The main questions it aims to answer are:\n\nDoes MM09 reduce the symptoms and the need of rescue medication? What medical problems do participants have when inhaling MM09? Researchers will compare MM09 to a placebo (a look-alike substance that contains no drug) to see if MM09 works to treat rhinitis\u002Frhinoconjunctivitis.",[32,63],"Rhinoconjunctivitis",[65,66,67,68,69,70,71,72,73,74,75,76],"immunotherapy","sublingual","Quality of live","dust mites","Dermatophagoides pteronyssinus","Dermatophagoides farinae","moderate asthma","allergic rhinitis","Allergic asthma","House dust mite allergy","efficacy","safety","2026-01-09",{"date":79,"type":38},"2026-01-16",{"date":81,"type":38},"2025-04-02",{"date":83,"type":22},"2029-07",{"name":85,"class":86},"Inmunotek S.L.","INDUSTRY",19,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":46},"100538481","nasal-packing-duration-and-development-of-pharyngitis-after-septorhinoplasty-surgery-100538481","NCT06291402","Nasal Packing Duration and Development of Pharyngitis After Septorhinoplasty Surgery","Nasal Packing Duration and Its Role in the Development of Pharyngitis After Septorhinoplasty Surgery: A Prospective Observational Study","Inclusion Criteria:\n\n* ASA I and II patients\n* aged from 20 to 40 years old\n* undergo septorhinoplasty\n\nExclusion Criteria:\n\n* Bleeding disorders\n* Uncontrolled hypertension\n* Cardiovascular diseases\n* Uncontrolled diabetes mellitus\n* Collagen disorders\n* Pregnancy","20 Years","40 Years",{"count":98,"type":22},100,"OBSERVATIONAL","Septoplasty or septal reconstruction is a corrective surgical procedure performed to straighten the nasal septum. It may be associated with numerous complications. To minimize these complications, both nasal cavities are frequently packed with different types of nasal packing. In our study we will try to find relationship between duration of nasal packing and postrhinoplasty sore throat and pharyngitis.",[32],"2026-01-04",{"date":104,"type":38},"2026-01-06",{"date":106,"type":38},"2024-03-10",{"date":108,"type":22},"2025-12-30",{"name":110,"class":45},"Al-Azhar University",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":46},"100358882","intranasal-capsaicinoid-spray-100358882","NCT03952845","Intranasal Capsaicinoid Spray","Tolerability of Intranasal Capsaicinoid Spray","Inclusion Criteria:\n\n* Healthy adults\n* American Association of Anesthesiology Class 1,\"A normal, healthy patient\" only\n\nExclusion Criteria:\n\n* Age less than 18 years\n* Pregnancy\n* Previous nasal or paranasal sinus surgery or radiation\n* Allergies to capsaicinoids or capsaicinoid containing products (any combination of sweet peppers, or hot peppers).",true,{"count":120,"type":22},30,[25],"Rhinitis is inflammation of the inside of the nose. Symptoms of rhinitis include itchiness, sneezing, and a \"runny\" nose (rhinorrhea). There are many different causes for rhinitis, including allergies, age, different irritants in the air, overacting nervous system, and others.\n\nMany current treatments for rhinitis are not helpful or are unable to be used for long periods of time. Capsaicin (\"Kap-Sey-Uh-Sin\") is a natural product that is found in many spicy foods, including hot peppers. This natural product has been used as a lotion to prevent pain, and scientists have found that it may reduce the symptoms of rhinitis when used as a spray in the nose.\n\nHowever, capsaicin is known to cause a burning sensation. This study is needed so we can figure out what doses of capsaicin cause this burning sensation, and to what level these doses cause discomfort. Capsaicin can also cause a small degree of tearing from the eyes when used as a spray in the nose, and can also cause the nose to become \"runny\" (rhinorrhea).\n\nWhen the safest dose of capsaicin spray is found, that dose can be used to treat people with rhinitis that is not getting better from standard treatments.",[124,125,32],"Tolerance","Capsaicin",[125,32],"NOT_YET_RECRUITING","2024-08-19",{"date":130,"type":38},"2024-08-21",{"date":132,"type":22},"2025-08-01",{"date":134,"type":22},"2030-12-01",{"name":136,"class":45},"Nova Scotia Health Authority",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":144,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100554419","efficacy-of-two-nasal-products-based-on-diluted-seawater-in-the-treatment-of-upper-respiratory-infectionsconditions-100554419","NCT06498843","Efficacy of Two Nasal Products Based on Diluted Seawater in the Treatment of Upper Respiratory Infections\u002FConditions","Clinical Evaluation of the Effectiveness of Nasal Pump Spray Medical Devices DM004 and DM020 Based on Diluted Seawater in the Treatment of Colds, Rhinitis, Sinusitis, and Other Upper Respiratory Infections\u002FConditions","Inclusion Criteria:\n\n* Autonomous adult, or minor with the consent of their legal representative\n* Adults and children from 3 months old\n* Ability of the patient (for adults) or their legal representative (for children) to follow the instructions for product use\n* Having signed a free and informed consent to participate in the study expressed by the patient (for adults) or by their legal representative (for children) after being informed by the doctor.\n* Person with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis…) with symptoms of nasal congestion and nasal discharge of moderate to severe intensity (Jackson derived score (nasal congestion + nasal discharge) ≥ 4 on Day 0).\n* Persons with symptoms that started no more than 48 hours before the first visit\n\nExclusion Criteria:\n\n* Person not showing cold symptoms, particularly no nasal congestion (chronic dry rhinitis, or Jackson derived score (nasal congestion + nasal discharge) \\< 4 on Day 0).\n* Person undergoing treatment with a cortisone derivative, mucolytic, or medication containing pseudoephedrine or a similar product acting on nasal congestion or having used such a product within the 3 days preceding inclusion.\n* Person having used a nasal wash product within the 3 days preceding inclusion.\n* Person whose ability to use the product daily and complete the daily follow-up diary is in doubt.\n* Person refusing to sign the informed consent form prior to the study.\n* Person participating or having participated in any other clinical study within the 30 days preceding the study.\n* Person participating in any other clinical study.","3 Months",{"count":146,"type":22},91,[25],"The goal of this interventional clinical trial is to test the safety and efficacy of two medical devices in subjects aged from 3 months old for the treatment of colds, rhinitis, sinusitis, and other upper respiratory infections\u002Fconditions for 7 days.",[32,150,151,152],"Sinusitis","Upper Respiratory Infections","Colds","2024-07-31",{"date":155,"type":38},"2024-08-02",{"date":157,"type":22},"2025-01",{"date":159,"type":22},"2025-06",{"name":161,"class":86},"YSLab",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":169,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":46},"100543021","washed-microbiota-transplantation-for-rhinitis-100543021","NCT06350448","Washed Microbiota Transplantation for Rhinitis","Efficacy and Safety of Washed Microbiota Transplantation for Rhinitis","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to enter the study:\n\n1. Age ≥ 6 years.\n2. Patient should have two or more nasal symptoms （nasal congestion, rhinorrhea, nasal itching, and sneezing） for at least 1 hour daily.\n3. Reflective total nasal symptom score ≥ 4\n4. The subject or his\u002Fher legal representative gives informed consent, fully understands the purpose of the study, is able to communicate effectively with the investigator, and comprehends and complies with the requirements set forth in the study.\n\n   \\-\n\nExclusion Criteria:\n\nSubjects meeting any of the following exclusion criteria must be excluded from the study:\n\n1. Patients with acute infectious rhinitis or upper respiratory tract infection.\n2. Patients diagnosed with chronic sinusitis, severe nasal septum deviation, nasal polyps, nasal tumors, and other nasal diseases by nasal endoscopy and sinus CT.\n3. Antibiotics, PPI, probiotics, and other drugs that alter gut microbiota were used in the previous week.\n4. Patients with uncontrolled severe asthma\n5. Patients with severe liver, kidney, and heart diseases\n6. Patients with known psychiatric or neurological diseases.\n7. Patients who were unable or unwilling to undergo a gastroscopy or colonoscopy.\n8. According to the judgment of the investigator, the subjects are not suitable to participate in this clinical study, or participation in this clinical study cannot guarantee the rights and interests of the subjects.\n\n   \\-","6 Years",{"count":171,"type":22},40,[25],"The common symptoms of rhinitis include nasal itching, sneezing, anterior or posterior nasal leakage, and nasal congestion. Rhinitis can be classified as allergic rhinitis (AR) and non-allergic rhinitis (NAR) based on the presence of a specific allergen. Increasing evidence showed that gut microbiota can influence the development of AR. Although few studies have reported the association between NAR and gut microbiota, we found that washed microbiota transplantation (WMT) could improve nasal symptoms, whether it is AR or NAR. This clinical trial aims to evaluate the efficacy and safety of WMT for rhinitis.",[32],[176,177,178,72,179],"washed microbiota transplantation","rhinitis","gut microbiota","non-allergic rhinitis","2024-04-01",{"date":182,"type":38},"2024-04-05",{"date":184,"type":22},"2024-05-01",{"date":186,"type":22},"2029-08-01",{"name":188,"class":45},"The Second Hospital of Nanjing Medical University"]